XML 70 R59.htm IDEA: XBRL DOCUMENT
v3.25.3

License and Collaboration Revenue and Other Funding Agreements, Viatris License Agreement (Details) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Nov. 06, 2022 USD ($) | Nov. 30, 2022 USD ($) | Sep. 30, 2025 USD ($) Performanceobligation | Sep. 30, 2024 USD ($) | Sep. 30, 2025 USD ($) Performanceobligation | Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($)
Contract Assets and Unbilled Receivables [Abstract] |  |  |  |  |  |  |
Revenue recognized |  |  | $ 3,079 | $ 3,867 | $ 10,331 | $ 6,690 |
Viatris License Agreement [Member] |  |  |  |  |  |  |
Collaboration and License Agreement [Abstract] |  |  |  |  |  |  |
Non-refundable cash payment received |  | $ 35,000 |  |  |  |  |
Maximum amount of payments receivable for development, regulatory and commercial milestones | $ 130,000 |  |  |  |  |  |
First milestone payments received | $ 10,000 |  |  |  |  |  |
Maximum percentage of tiered royalties receivable |  |  | 20.00% |  | 20.00% |  |
Number of distinct performance obligations | Performanceobligation |  |  | 2 |  | 2 |  |
Non-cancellation period of Constraint for Research and Development Revenue |  |  |  |  | 120 days |  |
Contract Assets and Unbilled Receivables [Abstract] |  |  |  |  |  |  |
Balance as of beginning of period |  |  |  |  | $ 2,209 | 1,407 |
Revenue recognized |  |  | $ 3,100 | 3,900 | 10,331 | 6,690 |
Balance as of end of period |  |  | $ 1,364 | $ 1,468 | 1,364 | 1,468 |
Viatris License Agreement [Member] | License Transfer Fee [Member] |  |  |  |  |  |  |
Contract Assets and Unbilled Receivables [Abstract] |  |  |  |  |  |  |
Reclassification to Accounts receivable related to costs billed under the Viatris License Agreement |  |  |  |  | (11,176) | $ (6,629) |
Viatris License Agreement [Member] | Sales Milestones [Member] |  |  |  |  |  |  |
Collaboration and License Agreement [Abstract] |  |  |  |  |  |  |
Milestone payment requirements attributed to the FDA's approval |  |  |  |  |  |  | $ 10,000
Contract Assets and Unbilled Receivables [Abstract] |  |  |  |  |  |  |
Revenue recognized |  |  |  |  | $ 0 |  |

X
- References No definition available. + Details
Name: | ird_CollaborationAndLicenseAgreementAbstract
Namespace Prefix: | ird_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current. + References No definition available. + Details
Name: | ird_ContractAssetCurrent
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This line item represents amounts invoiced that were previously reflected in the Contract Asset account. + References No definition available. + Details
Name: | ird_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestone payment received upon achieving performance obligation. + References No definition available. + Details
Name: | ird_FirstMilestonePaymentReceived
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payments receivable upon the achievement of development, regulatory and commercial goals. + References No definition available. + Details
Name: | ird_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The maximum percentage of tiered royalties receivable based on the aggregate annual net sales of all Nyxol Products in the United States. + References No definition available. + Details
Name: | ird_MaximumPercentageOfTieredRoyaltiesReceivable
Namespace Prefix: | ird_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of milestone payment met by the entity which required FDA's approval. + References No definition available. + Details
Name: | ird_MilestonePaymentRequiredUnderFDASApproval
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Non-cancellation period of constraint for Recognizing Research and Development Revenue, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | ird_NonCancellationPeriodOfConstraintForResearchAndDevelopmentRevenue
Namespace Prefix: | ird_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of non-refundable cash payments received during the period under the collaboration agreement. + References No definition available. + Details
Name: | ird_NonRefundableCashPaymentReceived
Namespace Prefix: | ird_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of performance obligations in accordance with the provisions under ASC 606, the Company identified. + References No definition available. + Details
Name: | ird_NumberOfPerformanceObligations
Namespace Prefix: | ird_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ird_ViatrisLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ird_LicenseTransferFeeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_HealthCareOrganizationRevenueSourcesAxis=ird_SalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |